Tools for Brokers is preparing to launch a new product called DEXA. The launch is scheduled for tomorrow (Wednesday). It is intended to expand the company’s brokerage infrastructure and risk technology stack.

The company has gradually extended its platform beyond liquidity connectivity. Its development work has focused on bringing execution, risk management, and analytics into a more connected environment. This reflects an industry shift toward consolidated broker infrastructure, rather than separate systems for each function.

DEXA Launch Targets Broker Risk Systems

The new system, DEXA, is described as an ultra-high-performance AI-powered analytics and risk management platform built for brokerages. In a LinkedIn post, Alexey Kutsenko said DEXA is intended to change how brokers manage their book, risk, and trading desks.

He said most risk desks still operate across multiple systems, including MT4/MT5 admin panels, bridge dashboards, and spreadsheets. He said this requires teams to manually piece together trading activity.

Kutsenko also mentioned that DEXA “consolidates this workflow into a single real-time command centre”. He added that it brings “all trading activity into one view that is refreshed every second”, allowing risk teams to track changes as they happen. He added the system is built to give risk teams “a full live picture of their book as it unfolds”.

The release adds to Tools for Brokers’ positioning in brokerage infrastructure. Execution, risk management, and analytics are increasingly converging in real time.

Trade Processor Gains Reporting and Splitting

Last year, the company partnered with TRAction to integrate automated regulatory reporting into Trade Processor. This allowed brokers to generate and submit reporting data through the platform instead of using separate external tools. It also introduced a large-order splitting feature to break down larger trades into smaller executions. This was aimed at improving execution handling and pricing outcomes.

This article was written by Tareq Sikder at www.financemagnates.com.Retail FXRead More

You might also be interested in reading MASH drug developers rise as FDA accepts lenient trial requirement.